International Assets Investment Management LLC Has $144,000 Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

International Assets Investment Management LLC lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 2,858.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,881 shares of the medical device company’s stock after purchasing an additional 4,716 shares during the quarter. International Assets Investment Management LLC’s holdings in Tandem Diabetes Care were worth $144,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of TNDM. RiverPark Advisors LLC bought a new stake in shares of Tandem Diabetes Care during the 4th quarter worth $27,000. PNC Financial Services Group Inc. lifted its position in shares of Tandem Diabetes Care by 51.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after buying an additional 1,099 shares during the last quarter. Creative Financial Designs Inc. ADV bought a new stake in shares of Tandem Diabetes Care during the 4th quarter worth $104,000. Stonebridge Capital Advisors LLC bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth $112,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of Tandem Diabetes Care by 10.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock worth $205,000 after buying an additional 908 shares during the last quarter.

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $37.05 on Tuesday. Tandem Diabetes Care, Inc. has a 1 year low of $13.82 and a 1 year high of $40.74. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of -10.77 and a beta of 1.11. The business has a 50-day moving average of $31.21 and a 200-day moving average of $25.61.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. As a group, equities research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Stifel Nicolaus upped their price objective on Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Wells Fargo & Company upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $21.00 to $45.00 in a research report on Monday. StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. Leerink Partnrs upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 25th. Finally, SVB Leerink upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and increased their target price for the company from $34.00 to $45.00 in a research report on Thursday, April 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.82.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.